DAX22.242 +0,8%ESt505.154 +0,8%Top 10 Crypto12,60 +5,9%Dow40.114 +0,1%Nas17.383 +1,3%Bitcoin83.240 +0,8%Euro1,1396 +0,1%Öl66,97 +0,7%Gold3.315 -1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 Tesla A1CX3T BYD A0M4W9 Alphabet A (ex Google) A14Y6F Deutsche Telekom 555750 RENK RENK73 Infineon 623100 Amazon 906866 Mercedes-Benz Group (ex Daimler) 710000 Siemens Energy ENER6Y Lufthansa 823212 Bayer BAY001 BASF BASF11 Volkswagen (VW) vz. 766403
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX geht höher ins Wochenende -- Wall Street letztlich fester -- Alphabet meldet Gewinnsprung - Deal mit Palantir -- BYD mit mehr Umsatz und Gewinn -- Merck, Intel, BioNTech, Apple, Bayer im Fokus
Top News
Wall Street geht unstet ins Wochenende: Dow stabil - NASDAQ schraubt sich ins Plus Wall Street geht unstet ins Wochenende: Dow stabil - NASDAQ schraubt sich ins Plus
Alphabet-Aktie gefragt: Google-Mutter mit Gewinnsprung - Partnerschaft mit Palantir Alphabet-Aktie gefragt: Google-Mutter mit Gewinnsprung - Partnerschaft mit Palantir
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Berliner Luft - Thomas Soltau und Feingold Research analysieren das Traderverhalten - heute im gettex-podcast mit Lars Reichel

ProVerum Welcomes Tyler Binney to the Board of Directors

25.04.25 14:00 Uhr

DUBLIN, April 25, 2025 /PRNewswire/ -- ProVerum Ltd., the developer of the ProVee® System for BPH, a minimally invasive solution for treating benign prostatic hyperplasia (BPH), announced today the appointment of Tyler Binney to its Board of Directors.

Tyler has an outstanding track record in driving commercial growth. Most recently, he served as President and CEO of Relievant Medsystems, Inc., which was acquired by Boston Scientific in November 2023 for an upfront payment of $850 million plus performance based earnouts. Prior to joining Relievant, Tyler served as President and General Manager of the Interventional Urology Business Unit of Teleflex and as Vice President of Sales for NeoTract prior to the Teleflex acquisition.

"I am thrilled to join the ProVerum Board at such an exciting time in the company's growth," said Tyler Binney. "The ProVee® System, truly has the potential to transform the way BPH is managed and treated. I look forward to contributing to that success and supporting ProVerum's executive management as they as they prepare to embark on commercialization."

"I'm delighted to welcome Tyler to the Board," said Paul Bateman, CEO. "Tyler brings a wealth of experience in launching disruptive technologies and developing high-growth companies. His knowledge and understanding of the BPH market will be invaluable as we work to launch our novel technology in the US."

Dave Amerson, the Chairman of ProVerum's Board of Directors added, "Having worked with Tyler for many years, I have firsthand knowledge of his ability to help drive rapid growth. His appointment brings huge value to ProVerum."

About ProVerum
ProVerum Ltd. is an innovative Dublin based company focused on the development of novel minimally invasive technologies to treat BPH. Our first product offering, the ProVee® System for BPH is an investigational device, limited by federal law to investigational use and not available for sale within the United States. For more information visit www.proverummedical.com or connect with us on X or LinkedIn.

Contact
Matt Monarski
VP, Marketing
matt.monarski@ProVerumMedical.com

Cision View original content:https://www.prnewswire.com/news-releases/proverum-welcomes-tyler-binney-to-the-board-of-directors-302437680.html

SOURCE ProVerum Limited